Lantheus Holdings closed a new $275 million term loan facility and a new $75 million five-year cash-flow revolver facility (CFR).

The transaction was led by JPMorgan Chase with Citizens Bank and Wells Fargo Securities as joint lead arrangers.

Net proceeds from the new term loan, together with approximately $15 million of cash on hand, were used to retire the remaining outstanding principal balance on the company’s previous $365 million term loan facility with Credit Suisse as administrative agent and pay accrued interest and related fees and expenses attributable to the transaction.

The new term loan has an interest rate of LIBOR + 4.50% and retains the prior term loan’s maturity date of June 2022 as well as its 1% mandatory amortization per year, adjusted to reflect the new principal amount. The new term loan was issued at an original issue discount of 99.75%.

The CFR is priced at LIBOR + 3.50% and replaces the $50 million asset-backed loan facility, which was undrawn at the time of closing of the refinancing. The CFR carries the same 0.375% unused line fee as the ABL and has an extended maturity date of March 2022. Funds available under the CFR may be used for working capital and other general corporate purposes.

“We remain committed to enhancing the company’s capital structure,” commented Jack Crowley, chief financial officer of Lantheus. “This transaction improves our credit profile, provides additional liquidity and gives the flexibility needed to effectively capitalize upon our strategic initiatives.”

Lantheus Holdings is the parent company of Lantheus Medical Imaging, focusing on the development, manufacturing and commercialization of diagnostic imaging agents and products.